Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21578389 | 0.93 | LMNA (0.39) | LMNAKDM4EMAPK1HIF1AEPHX1 | |
| SCHEMBL13773245 | 0.85 | — | — | |
| SCHEMBL13595547 | 0.82 | KDM4E (0.30) | KDM4EMAPK1HIF1A | |
| SCHEMBL8068088 | 0.82 | OPRM1 (0.39) | KDM4EMAPK1HIF1A | |
| SCHEMBL20061189 | 0.79 | LMNA (0.33) | LMNAHRH3 | |
| SCHEMBL7935092 | 0.79 | MEN1 (0.44) | LMNAHIF1A | |
| SCHEMBL23337630 | 0.79 | DPP7 (0.31) | — | |
| SCHEMBL18233190 | 0.79 | KISS1R (0.38) | KISS1RKDM4EMAPK1HIF1AEPHX1 | |
| SCHEMBL14509061 | 0.79 | KISS1R (0.38) | KISS1RKDM4EMAPK1HIF1AEPHX1 | |
| SCHEMBL22507527 | 0.77 | KISS1R (0.32) | LMNAKISS1RHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218073-A1 | IMMUNOMODULATORY ANTI-CD73 ANTIBODIES AND USES THEREOF | CORVUS PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024059834-A2 | DOWNREGULATING INOS TO INCREASE CAR-T KILLING | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240016838-A1 | ENGINEERED NK CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-01-18 | — | — | US | disclosed |
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | Bicyclerd Limited (GB) | 2023-09-05 | — | — | US | disclosed |
| US-20230273213-A1 | PEPTIDE DESIGN AND GALECTIN-3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-08-31 | — | — | US | disclosed |
| US-11739121-B2 | EPHA2 agonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230253066-A1 | DESIGNED PROTEINS FOR LIGAND BINDING | NATIONAL SCIENCE FOUNDATION | 2023-08-10 | — | — | US | disclosed |
| US-20230242586-A1 | RAS INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
| US-20230227798-A1 | MODIFIED THERMOCCOCUS POLYMERASES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-07-20 | — | — | US | disclosed |
| US-11701434-B2 | Tertiary amino lipidated cationic peptides for nucleic acid delivery | NUTCRACKER THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-9896688-B2 | Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage | SIRNA THERAPEUTICS, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20160068837-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | SIRNA THERAPEUTICS, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-9012603-B2 | Peptides that block the binding of IgG to FcRn | BIOGEN IDEC HEMOPHILIA INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8461128-B2 | Anti-microbial agents and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-06-11 | — | — | US | disclosed |
| US-8299266-B2 | Processes for making epothilone compounds and analogs | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120178941-A1 | PROCESSES FOR MAKING EPOTHILONE COMPOUNDS AND ANALOGS | BRISTOL-MYERS SQUIBB COMPANY | 2012-07-12 | — | — | US | disclosed |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | SYNTONIX PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
| US-20090170805-A1 | ANTI-MICROBIAL AGENTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
| US-20070275904-A1 | CONJUGATES OF AZIRIDINYL-EPOTHILONE ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-29 | — | — | US | disclosed |
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218073-A1 | IMMUNOMODULATORY ANTI-CD73 ANTIBODIES AND USES THEREOF | NT5E, ENTPD5, ENTPD1 | LMNA 3087/4885KISS1R 4608/4885KDM4E 1596/4885 |
| US-20230242586-A1 | RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | LMNA 3854/4885KISS1R 4657/4885KDM4E 3362/4885 |
| US-11739121-B2 | EPHA2 agonists and uses thereof | EPHA2, EPHB2, EPHA6 | LMNA 1357/4885KISS1R 1358/4885KDM4E 1375/4885 |
| US-20160068837-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | NSUN2, AGO2, NSUN3 | LMNA 1298/4885KISS1R 3452/4885KDM4E 3446/4885 |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | FCGRT, FCGR3B, FCGR1A | LMNA 4348/4885KISS1R 2168/4885KDM4E 4111/4885 |
| US-20230273213-A1 | PEPTIDE DESIGN AND GALECTIN-3 INHIBITORS | LGALS3BP, LGALS3, LGALS1 | LMNA 862/4885KISS1R 3276/4885KDM4E 4847/4885 |
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | VIP, NGLY1, GRPR | LMNA 2134/4885KISS1R 885/4885KDM4E 4859/4885 |
| US-20070275904-A1 | CONJUGATES OF AZIRIDINYL-EPOTHILONE ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | FOLR1, FOLR2, DHFR | LMNA 4646/4885KISS1R 527/4885KDM4E 3220/4885 |
| US-11701434-B2 | Tertiary amino lipidated cationic peptides for nucleic acid delivery | LNPEP, SLC7A1, APLNR | LMNA 686/4885KISS1R 2883/4885KDM4E 4304/4885 |
| US-20120178941-A1 | PROCESSES FOR MAKING EPOTHILONE COMPOUNDS AND ANALOGS | EPOR, PYCR1, AZI2 | LMNA 2898/4885KISS1R 316/4885KDM4E 2159/4885 |
| US-20090170805-A1 | ANTI-MICROBIAL AGENTS AND USES THEREOF | ACAT1, ACAT2, APEH | LMNA 4177/4885KISS1R 4323/4885KDM4E 1450/4885 |
| US-20240016838-A1 | ENGINEERED NK CELLS | PBK, KLRK1, BCL9 | LMNA 482/4885KISS1R 2395/4885KDM4E 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.